• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Chung Kevin bought $4,258 worth of shares (1,000 units at $4.26), increasing direct ownership by 12% to 9,435 units (SEC Form 4)

    10/1/24 4:47:46 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care
    Get the next $ICU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chung Kevin

    (Last) (First) (Middle)
    C/O SEASTAR MEDICAL HOLDING CORPORATION
    3513 BRIGHTON BLVD., SUITE 410

    (Street)
    DENVER CO 80216

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SeaStar Medical Holding Corp [ ICU ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.0001 per share 09/30/2024 P 1,000 A $4.2581 9,435(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.
    Remarks:
    /s/ Eric Schlorff, as attorney-in-fact 10/01/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ICU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

      DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

      5/7/25 10:00:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

      DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be viewed at https://youtube.com/live/ki1hFktn_2Y?feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical's website on the Events and Presentations pa

      4/30/25 8:05:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

      DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy. The two new Breakthrough Device Designations are indicated for the treatment of systemic inflammatory response in 1) adult patients undergoing cardiac surgery and 2) pediatric patients undergoing cardiac surgery towards prevention of post-operative adverse complicatio

      4/8/25 8:05:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Chung Kevin

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      4/3/25 7:33:39 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Green David A

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      4/3/25 7:33:07 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      2/27/25 3:51:55 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    SEC Filings

    See more
    • SEC Form DEF 14A filed by SeaStar Medical Holding Corporation

      DEF 14A - SeaStar Medical Holding Corp (0001831868) (Filer)

      5/7/25 9:05:41 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by SeaStar Medical Holding Corporation

      DEFA14A - SeaStar Medical Holding Corp (0001831868) (Filer)

      5/6/25 5:26:23 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by SeaStar Medical Holding Corporation

      EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)

      4/30/25 12:15:20 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Financials

    Live finance-specific insights

    See more
    • SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

      DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

      5/7/25 10:00:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic

      3/27/25 4:05:00 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

      DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S.   1 (646) 307-1963 from outside

      3/24/25 5:30:00 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SeaStar Medical Holding Corporation

      SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

      11/14/24 5:35:52 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      2/27/25 3:51:55 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Chung Kevin bought $8,458 worth of shares (4,250 units at $1.99), increasing direct ownership by 45% to 13,685 units (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      11/19/24 5:18:50 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Chung Kevin bought $4,258 worth of shares (1,000 units at $4.26), increasing direct ownership by 12% to 9,435 units (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      10/1/24 4:47:46 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care